Prevalence and clinical characteristics of rheumatoid arthritis in Poland : a nationwide study by Batko, Bogdan et al.
Clinical research
Corresponding author:
Bogdan Batko MD, PhD
Department 
of Rheumatology
J. Dietl 
Specialist Hospital
1 Skarbowa St
31-121 Krakow, Poland
Phone: +48 603 686 744
E-mail: bpbatko@gmail.com
1 Department of Rheumatology, J. Dietl Specialist Hospital, Krakow, Poland
2 Rheumatology and Autoimmune Diseases Department, Silesian Rheumatology 
Center, Ustron, Poland
3 Department of Rheumatology and Internal Medicine, Wroclaw Medical University, 
Wroclaw, Poland
4 Department of Internal and Agricultural Medicine, Jagiellonian University School  
of Medicine, Krakow, Poland
5 Department of Prevention of Environmental Hazards and Allergology,  
Medical University of Warsaw, Poland
6 GfK Polonia, Warsaw, Poland
Submitted: 9 August 2017
Accepted: 13 October 2017
Arch Med Sci 2019; 15, 1: 134–140
DOI: https://doi.org/10.5114/aoms.2017.71371
Copyright © 2017 Termedia & Banach
Prevalence and clinical characteristics of rheumatoid 
arthritis in Poland: a nationwide study
Bogdan Batko1, Marcin Stajszczyk2, Jerzy Świerkot3, Karol Urbański4, Filip Raciborski5,  
Mariusz Jędrzejewski6, Piotr Wiland3
A b s t r a c t
Introduction: There are no reliable data regarding the prevalence of rheuma-
toid arthritis (RA) in Poland.
Material and methods: The first stage was a face-to-face survey on a nation-
wide representative sample of 3000 people, which identified respondents with 
a physician-confirmed diagnosis of RA. The second stage was a survey of RA pa-
tients, which characterized the disease course and treatment. It was evaluated by 
analysis of a representative group of 1957 RA patients in routine clinical practice.
Results: The overall RA prevalence in Poland was 0.9% (95% CI: 0.6–1.2%), 
1.06% for women, 0.74% for men. Seventy-eight percent  were female, mean 
age was 56 and mean disease duration 7 years. Younger patients (< 50) 
remained professionally active in 90% of cases. Thirty percent of patients 
were diagnosed within 3 months of the first RA symptoms, while for 17% it 
took more than 1 year. Fifty-six percent of newly diagnosed patients were 
characterized by high disease activity (DAS-28 > 5.1). Presently, low disease 
activity (DAS-28 < 3.2) was found in 38.5% of patients. In Poland, 94% of pa-
tients have been treated with non-steroid anti-inflammatory drugs, almost 
80% with glucocorticoids. Meanwhile, methotrexate, as an anchor drug in 
Poland, has been used by 80% of patients, biological agents by 2.94% of 
patients.
Conclusions: This is the first cross-sectional population-based epidemiolog-
ical study regarding prevalence of RA in the adult Polish population. The 
results demonstrate a  high prevalence, falling within the upper boundary 
estimates for Europe. Despite ongoing treatment, the majority still have 
moderate to high disease activity, and the use of biological therapies is low.
Key words: rheumatoid arthritis, disease activity, epidemiology, disease-
modifying anti-rheumatic drugs.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease, with a ten-
dency to result in progressive joint damage and systemic complications. 
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Organ damage secondary to RA progression can 
lead to disability and premature death [1]. Epide-
miological data are needed for health profession-
als and policy makers to ensure an appropriate 
health care system. The prevalence of RA varies 
between countries with a  significant increase 
from southern to northern regions: 0.33% in Italy 
[2], 0.31% in France [3], 0.8% in Finland [4], and 
0.85% in England [5]. It is proposed that the geo-
graphical variability is associated with the severity 
of the disease [6]. Other differences are observed 
based on ethnicity. For instance, no cases of RA 
were diagnosed in the rural Nigerian population 
[7], whereas Pima Indians from Arizona are known 
for an exceptionally high RA incidence rate [8].
A  compelling observation is that overall RA 
prevalence has shown a declining tendency over 
the last few decades [9, 10], more visible in female 
disease distribution. Nevertheless, an increase of 
disease incidence due to ageing can be noted [11]. 
The incidence changes can be explained to an ex-
tent by different classification criteria over the 
years, when comparative studies were performed 
at different time points. The 1987 revised RA clas-
sification criteria caused a decrease of incidence 
by over 20% in the UK [5]. However, a systematic 
review based on the same criteria shows a  sur-
prisingly increasing RA prevalence in low- and 
middle-income countries [12].
While there are multiple studies in other Eu-
ropean countries, we still lack nationwide epide-
miological data in Poland. The health care system 
in our country is based on general practitioners 
(GPs), who are usually the first line physician the 
patients meet. Based on the symptoms and re-
sults of basic tests, patients are referred to a spe-
cialist when necessary. In Poland, it often takes 
a  few months to be seen by a  specialist. Mean-
while, according to guidelines, the treatment 
of RA should be initiated as soon as possible to 
achieve longstanding remission and reduce det-
rimental effects of the disease [13, 14]. Not only 
prevalence, but also the course of the disease has 
been reported to differ between the regions, with 
northern countries being associated with more 
severe disease [6, 15]. Different causes of this 
phenomenon are raised such as genetic variants 
of HLA-DRB1 [16, 17] or differences in socioeco-
nomic status [18]. The mentioned data indicate 
substantial cross-population differences in the 
course of the disease and are not fully compara-
ble to each other. That is why the RA prevalence 
data in Poland are so eagerly anticipated. Hence, it 
would be optimal to align the health system with 
real demands.
Our study consisted of two stages. The objec-
tive of the first was to obtain reliable data on the 
RA prevalence rate in Poland. The second stage 
consisted of the analysis of RA patients with re-
gard to disease activity and type of treatment. 
This information provides insight into clinical 
characteristics and effectiveness of therapy. Re-
cently published data indicate substantial differ-
ences between urban and rural areas in Poland, 
with a morbidity rate of 5–8 and 3.7–4 per 1000 
inhabitants respectively [19]. The authors sug-
gest that it may result from restricted access to 
rheumatologists and a higher proportion of undi-
agnosed patients. This underlines the need for re-
liable data to improve health care for RA patients 
in Poland.
Material and methods
Cross-sectional study
The first stage was carried out on a represen-
tative, nation-wide group of 3000 people aged 
15 years or more. The study was conducted under 
the Omnibus profile. Random-quota sample se-
lection was performed through the personal iden-
tification database (PESEL), with each ID having 
equal sampling probability. Each Polish citizen has 
his own PESEL number, so the sample was chosen 
from all Polish citizens. In the case of no response 
of the chosen person, another one was recruited 
from the same district of the same sex and age 
group. No additional conditions were considered 
in the selection process. The distribution of the 
sample reflects the country demographics, includ-
ing sex, education and place of residence. Quanti-
tative data were collected from a sample of 3000 
persons, the sample size chosen to be reflective of 
the general Polish population, requirements of the 
Omnibus program and researcher resources. Each 
participant was visited face-to-face by a trained in-
terviewer. The questionnaire was validated for the 
Polish RA population, and included questions re-
garding: (a) chronic conditions, (b) joint symptoms 
(pain, swelling, morning stiffness exceeding 1 h, 
motion restriction), (c) distribution of peripheral 
joint pain or swelling – recorded on the diagram, 
(d) present diagnosis of arthritis, (e) specialization 
of the physician stating diagnosis and current at-
tending physician, (f) drug use for joint symptoms 
(type, dosage, route of administration, treatment 
period). Patients may be unaware of conditions 
they suffer from, which could further confuse the 
proper diagnosis. In order to rectify this, questions 
were repeated several times in a different manner, 
adopting alternative nomenclature for symptoms 
and disease. Moreover, questions referred to the 
current clinical state; therefore, well-treated per-
sons presented few to no symptoms. To overcome 
this underestimation, only patients with a diagno-
sis confirmed by a specialist were taken into ac-
count. On the other hand, this approach underes-
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timates patients with symptoms still undiagnosed 
by a physician. The method was validated on two 
groups, 50 participants each, with confirmed RA 
and a control group without RA.
Analysis of patients with diagnosed 
rheumatoid arthritis
A hundred rheumatologists with at least 5-year 
experience completed detailed questionnaires 
about 20 sequential patients, each diagnosed with 
RA. Data were gathered between December 2014 
and February 2015 from 1957 patients. Physicians 
were chosen based on the centers they work in 
(based on information from the Polish Chamber 
of Physicians), so as to reflect the national struc-
ture of RA treatment in Poland. During data anal-
ysis overrepresentation of centers with biological 
treatment was observed. The problem arose from 
the fact that even though physicians were re-
cruited in a  center without biological treatment, 
they also worked in a facility with such treatment 
possibilities and could enroll those patients. It 
was overcome by giving such physicians appro-
priate weights. The questionnaire consisted of 
both closed and open-ended questions, reflecting 
among other things: (a) the diagnostic process, 
(b) indicators of RA activity at diagnosis and cur-
rently, (c) employment status, (d) medicines cur-
rently and previously used.
Ethical approval by decree of the Local Ethics 
Committee (Decision No. L.dz.OIL/KBL/OIL/9/214) 
and informed consent in accordance with the Hel-
sinki Declaration was obtained.
Results
Characteristics of patients
The first stage of the study revealed that over-
all RA prevalence in Poland was 0.9% (95% CI: 
0.6–1.2%), 1.06% for women and 0.74% for men. 
In the second stage, a total of 1957 patients with 
RA were analyzed, of whom 78% were female. 
The mean age was 56.77 ±13.9 (SD) years old. The 
mean disease duration was approximately 7 years, 
with 56% of patients diagnosed within the last 
5 years, after the appearance of the new EULAR/
ACR classification criteria. The ratio of economi-
cally active to inactive patients from the ages of 
51–60 was almost 1 : 1; however, younger pa-
tients (< 50) remained professionally active in 
approximately 90% of cases. Moreover, with a dis-
ease duration over 5 years, the activity rates did 
not exceed 36% (Figure 1). 
Time from symptoms to diagnosis
The mean time from onset of symptoms to first 
medical contact was ca. 3.5 months. In Poland 
71% of patients with RA were first seen by their 
GP, 13% by an internist, 10% by a rheumatologist, 
and the remainder by other specialists. Overall, 
30% of patients were diagnosed within 3 months 
from symptom onset but for 17% it took over 
1 year. The diagnosis of RA took approximately 
9 months on average (Figure 2). 
Characteristics of the disease
The patients were screened for disease activi-
ty at the time of diagnosis and when performing 
Figure 1. Economic activity of RA patients, by age (A) and disease duration (B)
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Figure 2. Time from beginning of symptoms to 
proper diagnosis
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the survey. 56% of newly diagnosed patients were 
characterized by a  high disease activity of DAS-
28 > 5.1. Presently, low disease activity of DAS-28 
< 3.2 was found in nearly 40% of patients; how-
ever, there was still a majority with DAS-28 > 3.2 
who had not achieved the goals of the RA treat-
ment guidelines (Table I).
Methods of treatment
The main sDMARD (synthetic disease-modify-
ing anti-rheumatic drug) is methotrexate, which 
was used at some time by 91% of patients (Ta-
ble II). Other frequently used drugs were sulfas-
alazine, leflunomide, and antimalarial drugs, with 
the occasional use of cyclosporine and gold salts. 
However, hydroxychloroquine and gold salts are 
not available on the Polish market. Seventy-five 
percent of patients were subject to glucocorti-
coid therapy, with 42% of patients continuing said 
therapy. The second most common drug group 
after methotrexate was non-steroidal anti-in-
flammatory drugs (NSAIDs). Nearly every patient 
was subject to NSAID treatment, with a recorded 
59% receiving them at the time of the survey. Di-
clofenac was the most common choice, used by 
one fourth of the patients. Only 2.9% of patients 
are currently treated with biological agents both 
reimbursed by the National Health Fund and hav-
ing undergone clinical trials.
Discussion
This is the first cross-sectional, population- 
based epidemiological study regarding RA in the 
adult Polish population. The results demonstrate 
a high prevalence of RA. They fall within the upper 
bound estimates for Europe, but are double the 
values from model-based estimates calculated for 
Poland by Kobelt and Kasteng [20]. Thus, accord-
ing to the south-north paradigm, Poland should 
be classified as a northern country. At the same 
time we should keep in mind that the observed 
differences are recently being questioned as sta-
tistically insignificant [21]. Second stage sex dis-
tribution of Polish RA patients is 3.5 : 1 (female: 
male), slightly higher than reported in other coun-
tries, though still consistent with other data from 
Poland [19] presented by Iltchev et al. That study 
compared RA prevalence in rural and urban areas 
in Poland but was based on information from the 
National Health Fund, included rheumatologist 
confirmed disease and did not include patients 
diagnosed in private medical practices. It showed 
an increasing morbidity rate of RA between 2008–
2012 from 4.6 to 6 per 1000 inhabitants, which 
was in part explained by the new 2010 diagnostic 
criteria. In contrast, we based our results on a rep-
resentative nation-wide group of people irrespec-
tive of the type of health care system the patient 
uses. Our results show even higher prevalence of 
0.9%. It may be caused by an increasing burden 
of RA but also by underestimation of the previous 
study. Hence, because of the different methodol-
ogy, comparing them in time and drawing conclu-
Table I. Indicators of RA activity, at time of diagnosis and current
Variable At diagnosis At last visit
Tender joint count Median (min, max) 8 (1, 16) 2 (0, 12)
Swollen joint count 4 (1, 15) 1 (0, 10)
DAS28-ESR 5.2 (3.0, 8.8) 3.7 (0.6, 8.2)
DAS28-ESR ≤ 2.6 % patients 0 26.1
2.61–3.2 1.5 12.4
3.21–5.1 42.7 50.7
> 5.1 56.0 10.8
Table II. Type of RA treatment, currently and pre-
viously used
Variable Currently 
used
Previously 
used
Synthetic DMARDs: 
Methotrexate 80.18 91.11
Sulfasalazine 14.43 41.17
Leflunomide 7.03 13.85
Chloroquine/
hydroxychloroquine
4.14 13.65
Cyclosporine 1.29 5.71
Gold salts 0.22 4.18
Biological DMARDs  
(in total)*:
2.94 4.66
Glucocorticoids 42.48 75.48
NSAIDs 58.9 94.08
*Treatment reimbursed by the National Health Fund and conducted 
clinical trials. Values indicate % of patients treated with a given drug
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sions about changes in disease prevalence in such 
short period should be undertaken with caution. 
As mentioned earlier, the decrease in prevalence 
of the disease, observed in the recent half century, 
can be partially attributed to implementation of 
the 1987 revised ACR criteria. However, a reverse 
trend can be observed with the appearance of the 
new 2010 ACR/EULAR criteria, which enable ear-
ly-stage RA diagnosis. Nowadays, there are projec-
tions of an increase in RA prevalence [22], which 
can be linked to an increase in life expectancy. As 
a result, patients diagnosed years ago live longer 
and do not decrease the disease prevalence rate, 
while new cases occur as usual and increase the 
number of patients. Our study does not have suf-
ficient statistical power to calculate prevalence in 
different age groups, which is restricted to reg-
istries. Although the age structure in our study 
shows that the majority of RA patients are in their 
sixties, they still fall within the younger percen-
tiles for Europe [20]. Moreover, register data from 
Sweden, characterized by longevity, show that 
crude and age-adjusted prevalence rates do not 
differ considerably [23].
GPs fulfill the central role in the Polish health-
care system. According to our data, in 71% of cas-
es they are the first medical contact of the patient 
after symptom onset. They order basic tests and 
refer the patient to a specialist, who in 90% of RA 
diagnoses is a  rheumatologist. Insurance condi-
tions in Poland limit the number of diagnostic pro-
cedures that can be conducted by a GP, of which 
anti-cyclic citrullinated peptide antibodies, other 
antibodies as well as imaging tests such as ultra-
sonography of joints, computed tomography and 
magnetic resonance imaging studies are restricted 
to specialists. After diagnosis, GPs mainly contin-
ue the treatment prescribed by a rheumatologist 
and deal with minor concerns (data not shown). 
Modification of chronic treatment is reserved for 
specialists. 
Time is of uppermost importance; diagnosis of 
RA should be established quickly to implement 
effective treatment – not only to relieve the symp-
toms but especially to halt joint damage, which 
may occur as early as the first few months [24], as 
well as to slow down occurrence of RA complica-
tions [25]. We can obtain highly successful treat-
ment of RA especially within 3 months of disease 
duration [26]. In our study, for nearly half of the 
patients, more than 2 months pass until the first 
contact with a physician occurs. Approximately 9 
months pass on average before the RA diagnosis 
is established. In order to improve the situation, 
a change must occur in patient awareness of the 
importance of the first arthritic symptoms and 
the necessity for physician consultation as ear-
ly as possible. Lag times differ from country to 
country. In Spain the first rheumatologist encoun-
ter occurs after 17 months from symptom onset 
[27]. In a  Canadian study 22% of patients re-
ceived DMARDs within 3 months and 48% within 
6 months, which is less than in our study. Howev-
er, the median lag time was shorter (6.4 months). 
It suggests a greater number of patients with very 
long lag times in our study. In other studies lag 
time delays were 4 months in Norway [28] and 
9 months in the United States [29]. In contrast, in 
Venezuela the lag time between symptom onset 
and RA diagnosis was as long as 40 months [30]. 
The main cause of these differences mentioned 
by all authors is the number of and access to 
rheumatologists.
According to Kobelt’s et al. report [20], Poland 
is close to the European average regarding num-
bers of RA patients per rheumatologist. It should 
be noted that for Poland Kobelt’s et al. estimate 
was 0.49%, while our data indicate a nearly dou-
bled RA prevalence rate of 0.9%. After this adjust-
ment, with about 300 RA patients per rheumatol-
ogist, we have one of the lowest indices in Europe. 
Moreover, the prediction for the upcoming years 
is not favorable. In 2009, 30% of rheumatologists 
were over 60 years old [31]. Earlier retirement age 
may further increase the shortage of rheumatolo-
gists in the future.
The primary form of RA treatment rests upon 
conventional sDMARDs. The anchor drug in Poland 
is methotrexate, which is in accordance with current 
guidelines indicating it as the first line treatment. 
Other DMARDs are much less frequently used, with 
the exception of sulfasalazine, which was used at 
some point by 40% of patients. Non-steroid anti- 
inflammatory drugs and glucocorticosteroids are 
very frequently used by RA patients. The COMORA 
study gave similar results, although high internation-
al variability was observed [32].
Most NSAIDs (excluding ibuprofen) are avail-
able in Poland mainly upon prescription, which 
prevents excessive and inappropriate use. These 
drug groups are considered symptomatic drugs 
and should only be used for a  limited period of 
time. The goal is to control the disease through 
use of DMARDs, while chronic NSAID use may be 
regarded as treatment failure. Indeed, at the last 
visit over 60% of patients had high or intermedi-
ate disease activity in DAS28-ESR and did not ful-
fill disease control criteria. The results of our study 
suggest a necessity for optimizing the treatment 
strategy, with synthetic and biological DMARDs. 
Unfortunately, the use of biological agents in Po-
land is low (2.9%, of which 13% are in clinical tri-
als), while in Sweden it applies to one fourth of 
RA patients [23]. Compared to other European 
countries, Poland has one of the lowest indices 
of biological treatment [20]. The main cause of 
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this situation is too little funds allocated to this 
kind of treatment. Criteria which must be met to 
get expensive biological drugs refunded in Poland 
are restrictive and not all patients can be treat-
ed according to guidelines. For a certain group of 
patients, biologic treatment may be the only op-
portunity for improved disease control, reduced 
symptomatic drug use and a  resulting improve-
ment in quality of life and employment. The loss 
in economic activity is observed after 5 years of 
disease duration and in the sixth decade of life 
(Figure 1). For younger RA patients (< 50 years 
old) activity rates are comparable to the overall 
population based on data available from the Cen-
tral Statistical Office and Eurostat, but in the sixth 
and seventh decades they are decreased, with the 
biggest fall concerning people in their fifties (sixth 
decade – 54.4% RA vs. 69.7%; seventh decade – 
17.7% RA vs. 20.3%).
The strength of the first stage of the study lies 
in the methodological approach with a  face-to-
face interview, which allows for a more compre-
hensive interview of the patient (compared to 
telephone surveys), followed by a recorded con-
firmation of current drugs (including DMARDs) in 
use. Moreover, only respondents with a special-
ist-confirmed diagnosis of RA were considered 
in the data, rheumatologists constituting 98% 
of them – the resulting limitation being the 2% 
of patients for whom the diagnosis was made by 
a specialist other than a rheumatologist, with no 
secondary confirmation. An apparent limitation is 
the second part of the study, being a retrospective 
analysis. Furthermore, the changing classification 
criteria throughout patient observation impact 
the precision of results concerning diagnosis.
In conclusion, this is a  unique epidemiologi-
cal study in the Polish population, which demon-
strates higher prevalence of RA in comparison to 
previously calculated estimates, and is therefore 
crucial for policymakers devising a healthcare sys-
tem. Retrospective analysis indicates a necessity 
for earlier diagnosis and optimization of therapy 
accordingly, since the majority of patients still ex-
hibit moderate to high disease activity. Achieving 
this requires constructive education of first con-
tact physicians and patients in terms of symptom 
significance and disease characteristics, coincid-
ing with an improvement of access to consulta-
tion with a rheumatologist.
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